August – September 2026 Counterfeit Drug News Roundup

Short on time? Two Months in Two Paragraphs.

In August and September 2026, counterfeit medicines reached the most trusted points in the supply chain. In India, suspected fake cancer drugs were allegedly supplied to more than 90 Bengaluru hospitals, weeks after Delhi police arrested hospital employees in an oncology racket. Lab testing showed that black market retatrutide rarely contains what its label claims. One Australian lab matched only 1 of 18 samples, and one vial held a dangerous dose of semaglutide instead. Fake Botox put patients in hospitals in Montenegro and Ukraine. In the UK, criminals stopped copying brands and launched their own.

The common thread is that every trust signal was faked or bypassed. Batch numbers, expiry dates, certificates of analysis, CE markings and a LegitScript seal all failed to protect patients. The fakes caught early were caught on physical evidence, such as wrong fonts, oversaturated ink or a pack a patient thought looked different. Enforcement is rising, from pill press arrests in the US to tougher penalties proposed in Portugal and Nigeria. But detection still depends on someone noticing. Non-additive authentication closes that gap by reading what the genuine product already is, in seconds, from a photograph.

Counterfeit Medicine Roundup: August and September 2026

Two months, and one finding that kept coming back from the lab: the label was wrong.

In Australia, a vial sold as retatrutide held a massive dose of semaglutide instead. In New York, bodega vials of four different peptides contained none of the ingredients printed on them. In Bengaluru, cheap bulk drugs were allegedly poured into fresh vials and relabeled as premium imported cancer medicines. In Mexico, regulators flagged genuine-looking packs carrying altered expiry dates.

The package told one story. The contents told another. And in almost every case, nobody could tell until a patient was harmed or a sample reached a lab.

Here is what happened, and what it says about where the threat is going.

India’s cancer drug fakes reached the hospital pharmacy

India produced the biggest counterfeit story of each month, and both ran through hospitals.

On August 20, Delhi Police’s Crime Branch announced it had dismantled an interstate syndicate trafficking counterfeit and diverted anti-cancer medicines worth roughly Rs 9 crore. Seventeen people were arrested. Investigators recovered 588 filled vials and six empty ones, along with packaging material, registers and about Rs 50 lakh in cash. The seized products included Darzalex, Imfinzi, Erbitux, Gazyva, Bavencio, Adcetris and Keytruda.

Four of those arrested were employees of leading cancer hospitals. Police say the network stole drugs, vials and packaging directly from private hospitals to repackage counterfeit versions. It also moved genuine medicines diverted from hospitals and government warehouses. That means some of the product in this case was authentic, with authentic codes, moving through illegitimate hands.

Three weeks later, a second case surfaced in Karnataka. It began with an August 18 seizure of medicines and equipment worth about Rs 4.91 crore at an unauthorized facility near Bidadi. By mid-September, investigators believed the network had supplied suspected counterfeit cancer drugs, life-saving medicines and ICU injections to more than 90 hospitals and clinics in Bengaluru, often at discounts of around 50 percent.

Karnataka’s health minister described the alleged method: cheap bulk formulations repackaged in fresh vials and relabeled as premium imports. A pharmacy owner was arrested, a special investigation team ran searches in six states, and the state suspended an assistant drug controller accused of failing to inspect the pharmacy at the center of the case. Licenses of 17 distributors were suspended or canceled, including a local Pfizer depot. Investigators have stressed that the hospitals are not accused of knowingly buying fakes, and it is not yet known whether patients received them.

Two months, two cities, the same weak point. The fake did not arrive through a back alley. It arrived through procurement, at a discount, in packaging good enough to pass at a hospital pharmacy.

Retatrutide: the testing caught up with the hype

In June and July, the retatrutide story was warnings and harm reports. In August and September, the lab results arrived, and they were worse than the warnings.

An Australian drug testing laboratory analyzed 18 samples sold as retatrutide. Only one matched its label. Roughly 30 percent held more peptide than advertised, 30 percent held less, and one held none at all. The lab noted the peptide typically makes up about 10 percent of a vial’s contents, leaving the rest unaccounted for. Australian authorities say they have destroyed more than 94,500 unapproved peptide products this year.

In mid-September, an Australian patient was hospitalized with a torn esophagus after uncontrollable vomiting. Testing found the vial contained no retatrutide. It held an exceptionally high dose of semaglutide, the active ingredient in Ozempic. Australia has now recorded at least seven cases of acute liver injury linked to products sold as retatrutide.

The pattern held in the United States. After CBS News reported peptides being sold in New York bodegas, a laboratory found that four vials bought at a Brooklyn smoke shop did not match reference samples. In September, WIRED reporters bought and tested bodega vials of PT-141, NAD+, BPC-157 and retatrutide. None contained the active ingredient on the label, and the lab could not say what they did contain.

The first outcome data pointed the same way. A preprint study, still in peer review, compared black market retatrutide users with Eli Lilly’s trial participants. Trial participants lost 15.5 percent of body weight at one year. Black market users lost 7.2 percent.

Harm reports kept coming. UK doctors told the BBC that young, fit patients were arriving at hospitals, some with kidney failure. Irish hospitals warned against the drug after a patient injected by a personal trainer was admitted with vomiting and kidney disease. A Montana woman went into anaphylaxis within an hour of injecting a black market peptide, with her heart rate falling below 20 beats per minute.

Eli Lilly escalated. On August 12, it filed six lawsuits against online sellers, med spas and a compounding pharmacy. It then told investors it was pressing payment processors, e-commerce sites, shippers and social platforms to block sales, and issued similar warnings in Canada. In the UK, Lilly and Novo Nordisk announced joint efforts using court orders and social media takedowns. Dutch inspectors banned an online seller from marketing retatrutide, semaglutide and tirzepatide.

The trust signals failed too. CBS News found at least 35 businesses selling retatrutide and other peptides while displaying LegitScript certification. A seal meant to tell consumers a seller was legitimate became part of the sales pitch.

Counterfeiters started building their own brands

One September detail from the UK deserves more attention than it got.

The Medicines and Healthcare products Regulatory Agency froze more than £200,000 across three bank accounts tied to Alluvi Healthcare, following four raids that produced large seizures of illegal weight-loss drugs. An MHRA official told the BBC it was the first time he had seen suspected criminals create their own brand rather than copy an existing one.

That is a meaningful shift. A counterfeit of Ozempic can be compared against Ozempic. An invented brand has no genuine reference to fail against. It builds its own trust from scratch, with its own packaging, its own website and its own social following.

Ukraine showed the copied-brand version at scale. Authorities approved more than 250 searches in an investigation into counterfeit Biopatid, a tirzepatide weight-loss product. The batch was attributed to a manufacturer that the Partnership for Safe Medicines had already flagged as suspicious in US import records in 2025.

The paperwork is being faked as well. In August, a US federal judge sentenced the owner of a peptide company to 70 months for selling unapproved drugs. Prosecutors said the company used forged laboratory certificates to market research chemicals as high-purity and US-made. In September, a federal jury convicted a Texas man who sold misbranded and unapproved drugs through websites and a Facebook group under “research use only” labels, sending more than 10,000 shipments and collecting over $1.4 million.

When the brand, the certificate of analysis and the label can all be manufactured, the only thing left to check is the physical product itself.

The fakes that got caught were caught by their packaging

Across both months, the counterfeits that were stopped early were stopped by someone noticing that the pack looked wrong.

In August, Kenya’s Pharmacy and Poisons Board warned about a falsified batch of emergency contraceptives, batch T34197R, falsely attributed to Hungarian manufacturer Gedeon Richter. Two people were arrested. Every distinguishing feature the board listed was visual: a missing hot-melt tamper seal, oversaturated orange coloring, an incorrect logo, mismatched fonts on the authentication panel, and errors in the patient leaflet.

In September, authorities in Ho Chi Minh City warned of a potentially counterfeit batch of the hepatitis B drug Getino-B 300mg, batch 664F44. It was flagged because a patient noticed differences in the packaging. Kenya’s regulator then issued an alert on fake Lucentis eye injections, batches 18862110 and 18802112, and made an arrest.

On September 28, Mexico’s regulator Cofepris named falsified or tampered lots of Saizen, Bedoyecta and Buscapina Compositum, plus a Granulox wound spray flagged for an altered expiry date.

The list continued:

• Nigeria. NAFDAC Public Alert 037/2026 on August 9 warned of a suspected Pulmicort counterfeit sold as “Ulmicort.” In September, NAFDAC arraigned two men and a pharmaceutical firm over counterfeit Coartem malaria tablets that lab testing found contained no active ingredient.
• Maldives. The Food and Drug Authority warned against a counterfeit nivolumab batch, 8081399, following July’s WHO alert on falsified Darzalex.
• India. Misbranded Abhayrab rabies vaccines, batch KE25012, were seized in Delhi after failing a government potency test. Two people were booked in Lucknow over suspected fake Lipaglyn diabetes tablets, batch IB00327A. In Gujarat, officials seized 1,250 suspected counterfeit blood pressure tablets and inspected more than 30 businesses.
• Pakistan. Laboratory testing flagged nine cancer medicines as fake, substandard or unregistered, some with no active ingredient.

Notice how many of these alerts depend on a batch number. That works only after a fake is found and reported. Until then, the batch number on a counterfeit is usually a real one, copied from a genuine pack.

Fake Botox put patients in the hospital

Aesthetic injectables became one of September’s clearest harm stories.

Several women in Montenegro were hospitalized after receiving suspected counterfeit Dysport. Ukraine reported cases of botulism linked to cosmetic injections in three regions. Kuwait moved to block counterfeit Botox flagged through an INTERPOL alert. In August, Lebanese authorities in Beirut seized large quantities of smuggled and counterfeit Botox, dermal fillers and medicines, and Korean drugmakers moved against imported copycat aesthetic products.

In the United States, Massachusetts med spa owner Rebecca Fadanelli was sentenced to 46 months in federal prison for performing thousands of injections with counterfeit Botox and fillers imported from China and Brazil. Prosecutors said she falsely claimed to be a licensed nurse. Multiple clients were hospitalized with conditions including facial paralysis and infections.

Health Canada seized unauthorized injectables, including counterfeit Juvéderm, from an Ontario beauty lounge in August. In September it warned that counterfeit laser hair removal and therapy devices had been sold to Canadian clinics with falsified licenses.

The aesthetic market has the same ingredients as oncology: high prices, strong demand, buyers outside traditional pharmacy channels, and a product the end user cannot verify by looking at it.

Production moved closer to the patient

Nigeria’s regulator said out loud in September what the seizure data had been suggesting: counterfeiting is no longer only an import problem.

NAFDAC’s director of investigation and enforcement said Chinese-linked syndicates had shifted from shipping fakes into Nigeria to manufacturing and distributing them locally. The agency has begun closing illegal logistics facilities tied to the network. It reported 64 convictions of counterfeiters between June 2025 and June 2026, its highest ever, and put the value of fake and substandard goods seized or destroyed since 2023 at more than ₦1.54 trillion. Director-General Mojisola Adeyeye called for life imprisonment or the death penalty for offenders.

NAFDAC also reported removing 7,210 suspected fake, substandard or non-compliant products in a May to July surveillance sweep, 2,459 of them drugs and herbal products. In August, Nigerian police broke up a group repackaging counterfeit omeprazole, Viagra and Ampiclox, and Lagos police uncovered a distribution network allegedly operating across West Africa.

Thailand offered the same lesson in September. Police raided a counterfeit cough and allergy medicine operation and seized equipment and materials for up to 100,000 bottles. Investigators are still hunting the financier.

The border model still matters, though. In August, Tashkent customs seized more than 21 tons of a counterfeit antibiotic imported from China and falsely declared as Indian-made, the same week Uzbekistan intercepted 1,330 packages of counterfeits allegedly smuggled from Russia. Twenty-one tons is container freight moving through formal channels on falsified paperwork.

Local production and formal freight point to the same problem. In both, the fake is already inside the system before anyone has a reason to inspect it.

United States: pill presses, diversion and the compounding gray zone

The biggest US enforcement story went after the equipment, not the pills.

In September, federal agents arrested two principal managers and a former long-time employee of LFA Machines, a company that sells pill presses and tableting machines. An Arizona grand jury had indicted the company and the three men in August. Investigators allege they sold equipment knowing, intending, or having reasonable cause to believe it would be used to make counterfeit pills. The same month, the House unanimously passed the Stop Pills That Kill Act, which would require serialization of pill presses and key components and raise penalties for knowingly supplying equipment for illegal drug production.

Press seizures and sentencings continued in both months. A Massachusetts man got 21 years for a basement pill factory with two electric presses. A South Carolina man got more than 18 years for producing counterfeit pills on a press. A Michigan man was convicted over a stash house holding more than 160,000 pills and a press. Two Florida brothers were charged with selling counterfeit oxycodone containing nitazenes on the darknet after a fatal overdose in Virginia. On August 31, the Partnership for Safe Medicines reported press seizures across 13 states from February to July.

The chemistry inside fake pills kept changing. Cychlorphine, a newly documented synthetic opioid, has been linked to a rise in poisoning deaths after appearing in counterfeit pills. Fentanyl test strips cannot detect it.

Diversion and import cases rounded out the picture. A former operations manager at a New Jersey wholesale distributor was sentenced to 30 months for a scheme that fraudulently bought nearly $50 million in oncology and ophthalmology drugs for resale. CBP in Chicago intercepted a master carton shipment from China holding more than 10,000 tablets and 2,100 vials of unapproved medicines. In August, the Fourth Circuit upheld an injunction in Gilead’s case against alternative funding programs, finding that imported product lacking FDA track-and-trace information was materially different from the US version.

Compounding remained a gray zone where quality failures look a lot like counterfeiting to the patient. On September 18, the FDA warned Empower Pharmacy for producing large volumes of weight-loss drugs that were essentially copies of approved products, citing prescriber justifications repeated word for word. Three Texas compounders recalled glutathione injections for elevated endotoxin levels, and the FDA reported at least 30 adverse events tied to the first two recalls. Ohio’s pharmacy board suspended five facilities in September, including compounders shipping peptides that are not eligible for compounding.

A new eight-country consumer survey from Michigan State University’s Center for Anti-Counterfeiting and Product Protection found that one in five consumers had bought counterfeit medicines online, knowingly or not, often when the genuine drug was scarce.

Lawmakers and regulators tightened the rules

Several governments moved from case-by-case enforcement to structural fixes.

Portugal’s government began preparing legislation to make selling counterfeit drugs a specific criminal offense, closing a gap that had let the practice escape clear penalties. In the US, the Senate unanimously passed a bill in August allowing Customs and Border Protection to share data on suspected counterfeit shipments with rights holders, e-commerce platforms and carriers. The Partnership for Safe Medicines and the National Intellectual Property Rights Coordination Center formalized a joint investigative alliance.

At the state level, attorneys general from at least 19 states urged federal action on weight-loss drug ingredients from China linked to warehouses with ties to fentanyl production. Mississippi’s boards of nursing, pharmacy and medical licensure jointly told providers they may not compound, recommend or dispense “research-grade” peptides, and that patient waivers do not change that.

In the UK, the MHRA welcomed the sentencing of a man who supplied hospital medical devices, including neonatal feeding pumps, carrying invalid CE markings. The certification mark, like the batch number and the certificate of analysis elsewhere in this roundup, turned out to be just another thing that could be faked.

The through-line

Read across August and September and one thing stands out. Almost every trust signal in the supply chain was faked, borrowed or bypassed.

Batch numbers were copied from genuine packs. Expiry dates were altered. Certificates of analysis were forged. A LegitScript seal appeared on sellers breaking its rules. CE markings were invalid. In Delhi, the vials and packaging were genuine because they were stolen from hospitals. In the UK, criminals skipped the copy entirely and invented a brand of their own.

And behind every one of those signals, the contents were something else. A different drug. A wrong dose. No active ingredient at all.

The counterfeits that were caught early were caught on physical evidence: an oversaturated ink, a wrong font, a missing seal, a pack a patient thought looked different. That is the right instinct. It just cannot depend on a trained inspector or an alert patient happening to look closely on the right day.

This is the case for non-additive authentication. It does not add another code, seal or hologram for counterfeiters to copy. It reads what the genuine product already is: its artwork, print quality, color, typography and geometry. AI can compare those properties against the real thing in seconds, from an ordinary photograph, with no change to the packaging or the supply chain.

Every story above is a moment when someone could not tell the real from the fake fast enough. Closing that gap is the entire job.

Want to see how AI-powered, non-additive authentication protects your products and your patients? Talk to the TrueMed team.

Sources